Poolbeg Pharma active on several fronts, powered by capital-light model
Last updated: 16:13 29 Sep 2026 AEST, First published: 02:46 18 Jan 2022 AEDT
Snapshot
- Poolbeg Pharma funded to finish both trials as it courts partners for cancer drug
- Cavendish sees multi-billion-dollar prize as Poolbeg begins pivotal trial
- Poolbeg Pharma's POLB 001 immuno-modulator II receives fully-granted patent from US Patent Office
About the company
Poolbeg Pharma plc (AIM: POLB) is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company’s lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity. Poolbeg is also advancing the development of a patient-friendly therapy for obesity with an oral encapsulated GLP-1, offering a differentiated approach within one of the world’s largest markets. With multiple near-term clinical value inflection points, and an experienced team with a proven track record, Poolbeg is focussed on partnering its high value programmes that are targeting large markets and addressing critical unmet medical needs.
How it is doing
Poolbeg Pharma PLC (AIM:POLB) says both of its clinical programmes are now funded through to completion, with cash expected to last into the second quarter of 2028.
The focus for the rest of the year is recruiting patients into its TOPICAL trial of POLB 001, with more hospitals keen to join.
The company also expects to start a proof-of-concept study of its oral GLP-1 obesity treatment in the second half.
POLB 001 is being developed to prevent cytokine release syndrome (CRS), a potentially life-threatening immune overreaction triggered by some cancer immunotherapies.
Poolbeg Pharma PLC (AIM:POLB) has dosed eight patients in its TOPICAL trial, which is testing whether its drug POLB 001 can prevent a dangerous side effect of cancer immunotherapy.
The trial aims to recruit about 30 patients in total, with the first dosed in July.
Poolbeg Pharma PLC (AIM:POLB) told investors that its POLB 001 TOPICAL clinical trial will continue as planned after an interim safety review recommended no changes to the study protocol.
Patient recruitment is continuing across UK clinical sites, with further patients expected to be enrolled and additional centres activated as the trial progresses.
What the brokers say
Cavendish has reiterated its 'buy' rating on Poolbeg Pharma PLC (AIM:POLB), arguing that the drug developer's first patient dosing marks the start of a value-creating period for the shares.
The broker set a target price of 19p, implying upside of about 170% from the current 7.4p (up 5% on the day).
That gap captures the central tension in the investment case: a company with no revenue and a widening cash burn, set against what Cavendish believes is a drug with multi-billion-dollar peak sales potential.
What management says
Poolbeg Pharma PLC (AIM:POLB) chief legal officer John McEvoy joins Proactive's Stephen Gunnion with news that POLB 001's Immuno-modulator II has received the fully granted patent from the US Patent Office.
McEvoy explained the patent encompasses a class of drugs for treating and preventing hypercytokinemia (cytokine storms) in patients triggered by an immune response, applicable across multiple disease indications.
The granted patent further solidifies Poolbeg Pharma's robust intellectual property portfolio for POLB 001, potentially increasing the asset's value and making it more attractive to potential partners. McEvoy highlighted the company's ongoing efforts to strengthen and expand their IP portfolio, noting existing patents covering p38 MAP kinase inhibitors for influenza treatment and hypercytokinemia. Additional patents have been filed, particularly focusing on cancer immunotherapy applications of POLB 001.
Proactive Research
POLB 001 is a small molecule immunomodulator targeting Cytokine Release Syndrome (CRS) experience in severe influenza and other acute inflammatory conditions. The most recent data from the LPS challenge study earlier this year showed that it effectively reduces multiple inflammatory cytokines in a dose-dependent manner and has a good safety profile. Based on WHO data, Poolbeg estimates there may be 3-5mln severe influenza cases a year globally. The company has been granted patents in the US and Europe out to 2038.